The APAC cervical cancer diagnostic testing market is expected to grow from US$ 936.22 million in 2021 to US$ 1,351.28 million by 2028; it is estimated to grow at a CAGR of 5.4% from 2021 to 2028.
Healthcare players concentrate on several countries, owing to the large population suffering from cancer in these countries. Moreover, with rising production costs against their practices, these companies strive to produce sufficient revenue to entertain their investors. Having presence in growing countries offers reliable and profitable growth opportunities to the major players to lower their operating costs and expand their geographic reach. Advancements in biotechnology have increased the demand for improved diagnostics based on analytical systems in the healthcare market in several countries; they are also easing the shift toward point of care diagnostics kits. Fields such as infectious disease testing, molecular oncology, and pharmacogenomics in several countries open new growth avenues. Hence, healthcare companies are targeting patients or consumers from several economies. Companies in the healthcare sector have been investing significant amounts of their revenue in R&D activities to develop better and advanced offerings and technologies. Several countries across the region are going at a good rate. Several activities in the region propel the demand for metabolomics-related services. Thus, the rising prevalence of cancer and technological advancements in several economies are boosting the cervical cancer diagnosis test market and providing significant growth opportunities to the players operating in the APAC market.
In case of COVID-19, APAC is highly affected specially India. APAC countries are expecting to witness massive challenges due to increasing COVID-19. In light of the current economic scenario, healthcare companies have been badly impacted as a result of disease outbreaks. The outbreak has severely affected the tourism industry and imposed supply chain disruptions; moreover, low-income countries face additional challenges due to the shortage of healthcare infrastructure. Restrictive measures have been put forth in South Korea, Malaysia, Singapore, the Philippines, and India to prevent disease transmission. All these factors will impact the cervical cancer diagnostic test market for a short period of time. The government and population in the region are more focused on the treatment of COVID 19. The hospitals, and surgical centers are open for only emergency services. China is specifically facing issues that this epidemic has caused, leading to disruption of the supply chain, projected decreases in revenue and sales within all industries, as well as the concerns of health within the production factories and other public spaces. As the medical tourism is declined in response to the pandemic to the regions like South Korea and Japan which has negative impact on the country’s revenues. Thus, it is expected to have a negative impact on the cervical cancer diagnostic test market.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the APAC cervical cancer diagnostic testing market. The APAC cervical cancer diagnostic testing market is expected to grow at a good CAGR during the forecast period.
APAC Cervical Cancer Diagnostic Testing Market Revenue and Forecast to 2028 (US$ Million)
APAC Cervical Cancer Diagnostic Testing Market Segmentation
APAC Cervical Cancer Diagnostic Testing Market – By Type
- PAP Testing
- HPV Testing
- Colposcopy
- Cervical Biopsies
- Cystoscopy
- Others
APAC Cervical Cancer Diagnostic Testing Market – By Service Provider
- Diagnostics and Research Laboratories
- Hospitals and Clinics
- Specialty Clinics
- Home Care Services
APAC Cervical Cancer Diagnostic Testing Market, by Country
- China
- Japan
- India
- South Korea
- Australia
- Rest of APAC
APAC Cervical Cancer Diagnostic Testing Market - Companies Mentioned
- Abbott
- BD
- Cooper Companies, Inc.
- F. Hoffmann-La Roche Ltd.
- Femasys Inc.
- Guided Therapeutics, Inc
- Hologic, Inc.
- QIAGEN
- Quest Diagnostics Incorporated
